Skip to content
AGEN·Nasdaq·US

Agenus

Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. Its primary business is immuno-oncology, with antibody-based programs led by botensilimab, alone and in combination with balstilimab. It also holds an equity investment in MiNK Therapeutics and majority ownership of the vaccine adjuvant business SaponiQx.

Source: SEC 10-K Mar 16, 2026

Recent Activity

Updated Oct 10, 2026
–Agenus reported a 48% estimated three-year survival rate with its BOT+BAL combination therapy in recurrent ovarian cancer, as presented at IGCS 2026.
–The survival estimate remained stable at 48% between years two and three, indicating durable benefit of the treatment.
–These results were observed in a heavily pretreated, difficult-to-treat patient population.

Past updates are part of the Pro plan.

Thematic Position

AGEN

Relationship Groups

Suppliers2
Partners8
Licensing7
Competitors5

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

16 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

armed conflict
Russia's invasion of Ukraine may disrupt Agenus's Moscow subsidiary Atlant Clinical and partners
SEC 10-KMar 17, 2025

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.